Merck KGaA to Outlicense Osteoarthritis Clinical Program for Up to EUR450 Million
October 06 2020 - 9:10AM
Dow Jones News
By Joshua Kirby
Merck KGaA said Tuesday that it has agreed to outlicense the
clinical-stage program of a potential osteoarthritis treatment to
Novartis AG in a deal that could see the German pharmaceuticals and
chemicals company receive a total 450 million euros ($530.4
million).
Under the deal, Merck will outlicense to the Swiss drug maker
the Phase-2-ready M6495 treatment for further evaluation on
patients suffering from osteoarthritis. Merck will receive an
initial EUR50 million upfront, with a further EUR400 million
payable depending on certain development and commercial milestones
and royalties on future sales, it said.
M6495 is an anti-ADAMTS5 Nanobody that could, as a
self-administered treatment, maintain the integrity of knee joints
and reduce pain caused by osteoarthritis, Merck said.
Write to Joshua Kirby at joshua.kirby@dowjones.com
(END) Dow Jones Newswires
October 06, 2020 08:55 ET (12:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
